The startup’s first prospect is a heart medicine that works differently than the hypertrophic cardiomyopathy drugs developed by Bristol Myers and Cytokinetics.
The startup’s first prospect is a heart medicine that works differently than the hypertrophic cardiomyopathy drugs developed by Bristol Myers and Cytokinetics.
